Enanta Pharmaceuticals, Inc.
ENTA · NASDAQ
9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Market Cap | $255,392 | $219,187 | $234,224 | $1,068,678 |
| - Cash | $32,298 | $37,233 | $85,388 | $43,994 |
| + Debt | $201,056 | $226,058 | $222,441 | $26,686 |
| Enterprise Value | $424,150 | $408,012 | $371,277 | $1,051,370 |
| Revenue | $65,324 | $67,635 | $79,204 | $86,160 |
| % Growth | -3.4% | -14.6% | -8.1% | – |
| Gross Profit | $65,324 | $67,635 | $79,204 | $86,160 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$70,779 | -$104,512 | -$123,476 | -$119,215 |
| % Margin | -108.4% | -154.5% | -155.9% | -138.4% |
| Net Income | -$81,889 | -$116,045 | -$133,816 | -$121,755 |
| % Margin | -125.4% | -171.6% | -169% | -141.3% |
| EPS Diluted | -3.84 | -5.48 | -6.38 | -5.91 |
| % Growth | 29.9% | 14.1% | -8% | – |
| Operating Cash Flow | -$19,272 | -$78,764 | -$103,154 | -$84,782 |
| Capital Expenditures | -$12,896 | -$17,948 | -$9,058 | -$2,125 |
| Free Cash Flow | -$32,168 | -$96,712 | -$112,212 | -$86,907 |